Yes. And they have great reason to be excited, including the patients and families; there's a lot of potential Rett progress in the pipeline. And while gene therapy is still early days and quite difficult, Rett is a great target.
When you say "around the corner," does that mean on the market in 2022-23, or years later than that? Because if we can use that time frame rule for 2-73, I'd think that Anavex has multiple indications to be applied well before "around the corner."
Gene therapy for Rett is good news, but gene therapy may not be a cure. The article you cite, for example, mentions Zolgensma, an approved gene therapy for spinal muscular atrophy. Zolgensma is not a cure for SMA (spinal muscular atrophy). In addition, it cannot reverse any damage already caused by SMA before treatment. Zolgensma, however, has been beneficial in improving certain conditions caused by SMA, and it may help stop the progression of the disease.
Gene therapy may also have some serious side effects.
There may also be a need for other drugs or therapy even if some form of gene therapy for Rett is eventually approved.
Market Data 
Markets 
AI
